Peripheral Nerve Injuries

Approved for this indication (1)

• acellular nerve allograft

Phase 4 trials (2)

• gabapentin
• oxcarbazepine

Phase 3 trials (14)

• acetylcarnitine
• calcium citrate
• paclitaxel
• icosapent ethyl
• ixabepilone
• magnesium sulfate
• carboplatin
• cannabis
• oxaliplatin
• pregabalin
• aminophenazone cyclamate
• glutathione
• amniotic fluid
• polyethylene glycol

Phase 2 trials (20)

• amitriptyline
• epoetin
• bxq-350
• capsaicin
• lenalidomide
• ketamine
• dimiracetam
• eribulin
• ebselen
• tacrolimus
• iloprost
• Cambiogenplasmid
• tesamorelin
• nicotine
• cyclophosphamide
• rufinamide
• clonidine
• lacosamide
• psilocybin
• etoricoxib

Phase 1 trials (7)

• methylprednisolone
• bupivacaine
• autologous human schwann cells
• quercetin
• cenegermin-bkbj
• ab-101
• ct-044

Other trials (1)

• acetaminophen

Organization Involved with Phase 4 Indications (4)

• Astellas
• Aarhus University
• University of Southern Denmark
• European Commission

Organization Involved with Phase 2 Indications (10)

• GlaxoSmithKline
• Samyang Biopharmaceuticals Corporation
• Human Stem Cell Institute, Russia
• Johns Hopkins University
• University of Zurich
• Ruhr University Bochum
• Washington University in St. Louis
• Government of Canada
• Kazan Federal University
• Neuraptive Therapeutics Inc.

Organization Involved with Phase 1 Indications (3)

• University of Miami
• Vanderbilt University
• The Miami Project to Cure Paralysis